Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.

[1]  F. Lo‐Coco,et al.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. , 2012, Blood.

[2]  M. de Lima,et al.  Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation , 2011, Current opinion in hematology.

[3]  D. Weisdorf,et al.  Allogeneic stem cell transplantation in first complete remission , 2011, Current opinion in hematology.

[4]  K. Döhner,et al.  Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Z. Estrov,et al.  Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Thall,et al.  Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  E. Estey,et al.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Hokland,et al.  Towards individualized follow-up in adult acute myeloid leukemia in remission. , 2011, Blood.

[9]  D. Berry,et al.  Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Hoang Q. Nguyen,et al.  Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome , 2010, Cancer.

[11]  L. Rybicki,et al.  Effect of post-remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission , 2010, Leukemia & lymphoma.

[12]  M. Mohty,et al.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  C. Palacio,et al.  Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia , 2010, Haematologica.

[14]  J. Cornelissen,et al.  Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach. , 2008, Blood reviews.

[15]  F. Lo Coco,et al.  Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  I. Bernstein,et al.  131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. , 2006, Blood.

[17]  P. Thall,et al.  Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. , 2004, Blood.

[18]  C. Bloomfield,et al.  Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[20]  M. Horowitz,et al.  Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. , 2000, Blood.

[21]  J. Sierra,et al.  No impact of high‐dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission , 2000, British journal of haematology.

[22]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[23]  D. Grimwade,et al.  What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML Trial , 1997, Bone Marrow Transplantation.

[24]  J. Hancock,et al.  Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. , 1998, Blood.

[25]  E. Estey,et al.  Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. , 1992, Leukemia.

[26]  D.,et al.  Regression Models and Life-Tables , 2022 .